ECG Monitoring for Patients Taking Clozapine

Key ECG Parameters and Risk Factors

• The American Heart Association recommends monitoring for QT/QTc interval prolongation beyond 450ms in men and 470ms in women, with particular concern for QTc >500ms, which warrants immediate action, in patients taking clozapine 1
• The American College of Cardiology suggests looking for T wave abnormalities or enhanced U waves that may indicate increased risk of arrhythmias in patients taking clozapine 1
• The European Society of Cardiology recommends avoiding combinations with other QT-prolonging drugs when possible, as concomitant QT-prolonging medications can increase the risk of arrhythmias in patients taking clozapine 2
• The American Heart Association notes that patients with pre-existing QT prolongation, advanced age, electrolyte abnormalities, and cardiac disease are at higher risk for developing dangerous arrhythmias when taking clozapine 1, 2
• The European Heart Journal recommends considering repeating ECG after 2 weeks of treatment and after adding any new medication known to prolong QT interval in patients taking clozapine 3
• The Journal of the American College of Cardiology suggests that an increase in QTc of >60ms from baseline is considered clinically significant and requires urgent attention in patients taking clozapine 4

Warning Signs and Management

• The American College of Cardiology recommends immediate intervention if QTc exceeds 500ms, as this represents a significant risk threshold requiring urgent attention in patients taking clozapine 1
• The European Society of Cardiology suggests reviewing and adjusting concomitant medications that may contribute to QT prolongation in patients taking clozapine 2